Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model.

Publication Type:

Journal Article


Transplantation, Volume 90, Issue 1, p.14-22 (2010)


2010, Animals, Antibodies, Monoclonal, Antigens, CD44, Biologics Production Core Facility, Center-Authored Paper, Clinical Research Division, Comparative Medicine Core Facility, Cyclosporine, Dogs, Epidemiology Core Facility, Experimental Histopathology Core Facility, Flow Cytometry Core Facility, Graft vs Host Disease, hematopoietic stem cell transplantation, Immunosuppressive Agents, Major Histocompatibility Complex, methotrexate, Models, Animal, Mycophenolic Acid, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Transplantation Conditioning


Posttransplant cyclophosphamide has been shown to control graft-versus-host disease and facilitate engraftment in the major histocompatibility complex-haploidentical transplant setting. Here, we hypothesized that methotrexate (MTX) could be used in a similar fashion. In patients with genetic diseases, the use of MTX rather than an alkylating agent such as cyclophosphamide would be preferable due to its reduced risk of promoting secondary malignancies.